Wuhan Hvsen Biotechnology Co Ltd - Asset Resilience Ratio

Latest as of June 2026: 6.29%

Wuhan Hvsen Biotechnology Co Ltd (300871) has an Asset Resilience Ratio of 6.29% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Wuhan Hvsen Biotechnology Co Ltd current assets vs equity to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CN¥214.41 Million

≈ $31.37 Million USD Cash + Short-term Investments

Total Assets

CN¥3.41 Billion

≈ $498.82 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2020–2025)

This chart shows how Wuhan Hvsen Biotechnology Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see 300871 total assets.

Liquid Assets Composition Over Time

This chart breaks down Wuhan Hvsen Biotechnology Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Wuhan Hvsen Biotechnology Co Ltd for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CN¥0.00	0%
Short-term Investments	CN¥214.41 Million	6.29%
Total Liquid Assets	CN¥214.41 Million	6.29%

Asset Resilience Insights

Limited Liquidity: Wuhan Hvsen Biotechnology Co Ltd maintains only 6.29% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Wuhan Hvsen Biotechnology Co Ltd Industry Peers by Asset Resilience Ratio

Compare Wuhan Hvsen Biotechnology Co Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Wuhan Hvsen Biotechnology Co Ltd (2020–2025)

The table below shows the annual Asset Resilience Ratio data for Wuhan Hvsen Biotechnology Co Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	5.33%	CN¥160.33 Million ≈ $23.46 Million	CN¥3.01 Billion ≈ $440.25 Million	-1.34pp
2024-12-31	6.67%	CN¥200.97 Million ≈ $29.41 Million	CN¥3.01 Billion ≈ $441.14 Million	-3.56pp
2023-12-31	10.23%	CN¥304.26 Million ≈ $44.52 Million	CN¥2.98 Billion ≈ $435.40 Million	-1.87pp
2022-12-31	12.10%	CN¥361.68 Million ≈ $52.92 Million	CN¥2.99 Billion ≈ $437.40 Million	+11.00pp
2021-12-31	1.10%	CN¥30.22 Million ≈ $4.42 Million	CN¥2.74 Billion ≈ $401.19 Million	-12.63pp
2020-12-31	13.73%	CN¥240.63 Million ≈ $35.21 Million	CN¥1.75 Billion ≈ $256.41 Million	--

pp = percentage points

About Wuhan Hvsen Biotechnology Co Ltd

SHE:300871 China Biotechnology

Market Cap

$629.52 Million

CN¥4.30 Billion CNY

Market Cap Rank

#11099 Global

#3069 in China

Share Price

CN¥21.32

Change (1 day)

-0.56%

52-Week Range

CN¥19.24 - CN¥32.62

All Time High

CN¥48.84